171 related articles for article (PubMed ID: 38569945)
1. Epidemiology of NAFLD - Focus on diabetes.
Younossi ZM; Henry L
Diabetes Res Clin Pract; 2024 Apr; 210():111648. PubMed ID: 38569945
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of Non-alcoholic Fatty Liver Disease in North America.
Arshad T; Golabi P; Henry L; Younossi ZM
Curr Pharm Des; 2020; 26(10):993-997. PubMed ID: 32124690
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
Kuchay MS; Choudhary NS; Mishra SK; Misra A
Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
[TBL] [Abstract][Full Text] [Related]
5. Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics.
Younossi ZM; Henry L; Isaacs S; Cusi K
Endocr Pract; 2023 Nov; 29(11):912-918. PubMed ID: 37406857
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.
Alhinai A; Patel K; Fonseca VA; Sebastiani G
J Diabetes Complications; 2021 Sep; 35(9):107978. PubMed ID: 34183247
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease.
Isaacs S
Endocrinol Metab Clin North Am; 2023 Mar; 52(1):149-164. PubMed ID: 36754491
[TBL] [Abstract][Full Text] [Related]
9. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
Zhang X; Wong GL; Yip TC; Cheung JTK; Tse YK; Hui VW; Lin H; Lai JC; Chan HL; Kong AP; Wong VW
Hepatology; 2022 Nov; 76(5):1409-1422. PubMed ID: 35334125
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease.
Powell EE; Wong VW; Rinella M
Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
[TBL] [Abstract][Full Text] [Related]
12. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
[TBL] [Abstract][Full Text] [Related]
13. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
Zhu C; Zhou D; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
[TBL] [Abstract][Full Text] [Related]
15. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world.
Henry L; Paik J; Younossi ZM
Aliment Pharmacol Ther; 2022 Sep; 56(6):942-956. PubMed ID: 35880713
[TBL] [Abstract][Full Text] [Related]
16. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
Makri E; Goulas A; Polyzos SA
Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
